Search clinical trials for: germline heterozygous PTEN mutations

Total 1470 results

Boston Children's Hospital
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations

Autism | ASD | Macrocephaly | PTEN | PTEN Hamartoma Tumor Syndrome

United States
Stanford University

Not yet recruiting

Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations

PTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome | PTEN Hamartoma Syndrome

United States
Taiho Oncology, Inc.

Terminated

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

United States, United Kingdom, Austria, France
National Cancer Institute (NCI)

Recruiting

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid Malignancies

United States
National Cancer Institute (NCI)

Recruiting

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Mesothelioma | BRCA1-Associated Protein-1 (BAP1) Mutations | Malignant Mesothelioma (MM) | Early-stage Mesothelioma | Subclinical Mesothelioma | Early-stage BAP1-associated Malignancies

United States
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Breast Cancer Metastatic

China
European Institute of Oncology

Recruiting

LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients (LobularCard)

BRCA1 Mutation | BRCA2 Mutation | Lobular Breast Carcinoma | Lobular in Situ Breast Carcinoma

Italy
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers (PALB2-PARPi-01)

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
Prostate Cancer Clinical Trials Consortium
Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center; Sidney... and other collaborators

Recruiting

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Prostate Cancer

United States
National Cancer Institute (NCI)

Recruiting

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Mesothelioma | Familial Cancer | BRCA1-Associated Protein-1 (BAP1) Mutations | Tumor Predisposition Syndrome (TPDS)

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Bile Duct Adenocarcinoma | Fanconi Anemia Complementation Group Gene Mutation | Metastatic Bile Duct Carcinoma | PTEN Gene Deletion

United States
AZ-VUB
AstraZeneca; Kom Op Tegen Kanker

Recruiting

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes (1-2018 BSMO)

Advanced Cancers Harbouring Mutations in HRG

Belgium
National Cancer Institute (NCI)

Recruiting

Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes

Mesothelioma | Families

United States
UNICANCER
Institut National de la Santé Et de la Recherche Médicale, France; Gustave... and other collaborators

Recruiting

Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. (TUMOSPEC)

Mutation | Hereditary Breast and Ovarian Cancer

France
National Cancer Institute (NCI)

Recruiting

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

Stomach Neoplasms | Stomach Cancer | Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) | Hereditary Diffuse Gastric Cancer (HDGC) | Familial Diffuse Gastric Cancer

United States
Institute of Cancer Research, United Kingdom

Recruiting

Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations (GENPROS)

Prostate Cancer

United Kingdom
Johns Hopkins University
National Cancer Institute (NCI); National Institutes of Health (NIH); ChiRhoClin...

Recruiting

The Cancer of the Pancreas Screening-5 CAPS5)Study (CAPS5)

Lynch Syndrome | Pancreas Cancer | Gene Mutation | Peutz-Jeghers Syndrome (PJS) | Germline Mutation Carrier

United States
Sun Yat-sen University

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China
Amgen

Completed

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) (HAUSER-OLE)

Familial Hypercholesterolemia

Canada, Italy, Norway, Belgium, United States, Turkey, Australia, Austria, South Africa, Poland, Switzerland, Spain, Portugal, Slovenia, Brazil, Russian Federation, Hungary, United Kingdom, Colombia, Czechia, Netherlands, Greece, Ma...
National Cancer Institute (NCI)

Active, not recruiting

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
Dana-Farber Cancer Institute
Addario Lung Cancer Medical Institute

Active, not recruiting

INHERIT EGFR - Studying Germline EGFR Mutations (INHERIT)

Lung Cancer

United States
Faeth Therapeutics

Active, not recruiting

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Advanced Solid Tumor | PIK3CA Mutation | PTEN Loss of Function Mutation

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Clovis Oncology, Inc.

Active, not recruiting

Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

Prostate Cancer Metastatic

United States
Memorial Sloan Kettering Cancer Center
Cold Spring Harbor Laboratory

Active, not recruiting

Clinical Significance of Germline BRCA Mutations

Breast Cancer | Ovarian Cancer

United States
pharmaand GmbH

Terminated

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)

Solid Tumor

United States
European Institute of Oncology

Active, not recruiting

CDH1 Germline Mutations in Lobular Breast Cancer

Lobular Breast Carcinoma | CDH1 Gene Inactivation

Italy
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)

Metastatic Adenocarcinoma of the Pancreas | Germline BRCA1/2 Mutations and

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Germany, Korea, Republic of, Australia, Israel, Netherlands
M.D. Anderson Cancer Center
GlaxoSmithKline; National Comprehensive Cancer Network

Completed

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Solid Tumors | Advanced Cancers

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Terminated

Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

Cancer | Solid Tumors

United States
University Hospital, Montpellier

Completed

Consequences of Mutations in the SPG7 Gene at the Heterozygous State (CONSP-HET7)

SPG7

France
AstraZeneca

Completed

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

HER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 Mutations

Italy, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
Amgen

Completed

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders (HAUSER-RCT)

Heterozygous Familial Hypercholesterolemia

United States, Canada, Italy, Norway, Belgium, Turkey, Australia, New Zealand, Austria, Czechia, South Africa, Poland, Spain, Switzerland, Netherlands, Taiwan, Finland, Brazil, Portugal, Slovenia, Russian Federation, Hungary, United... and more
Instituto Nacional de Ciencias Medicas y Nutricion...

Completed

Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico

Pancreatic Cancer | Pancreatic Adenocarcinoma

Mexico
Memorial Sloan Kettering Cancer Center
University of Washington; Sarah Lawrence College

Completed

Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer

Breast Cancer

United States
AGO Research GmbH

Completed

Prevalence of BRCA in Patients With Ovarian Cancer

Ovarian Cancer | BRCA Status

Germany
National Cancer Institute (NCI)

Terminated

Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)

Genetics

Ukraine
Hellenic Cooperative Oncology Group

Completed

Germline Mutations in Pancreatic Adenocarcinoma (PaMPA)

Pancreatic Cancer | Hereditary Cancer | Predisposition, Genetic | Germline Mutation Abnormality

Greece
Yale University

Completed

Prostate Cancer Screening in Men With Germline BRCA2 Mutations

Prostate Cancer

United States
Peking University People's Hospital

Unknown

TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss (TQBSP)

Safety Issues | Efficacy, Self

China
National Cancer Institute (NCI)

Completed

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Li-Fraumeni Syndrome

United States
University of Minnesota

Completed

Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations

Urticaria Pigmentosa | Cutaneous Mastocytosis

United States
National Cancer Institute (NCI)

Terminated

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center
United States Department of Defense

Completed

Clinical and Histopathologic Characteristics of BAP1 Mutations

Renal Cell Carcinoma | Cholangiocarcinoma | Malignant Pleural Mesothelioma (MPM) | Choroidal Nevus | Primary Uveal Melanoma (UM) | Metastatic Uveal Melanoma (UM)

United States
University Hospital, Rouen

Completed

Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation (PANEL)

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Pediatric Cancers | Multiple Primary Malignant Tumours

France
AstraZeneca
Quintiles; University of Tubingen - Germany

Completed

International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study (BREAKOUT)

Breast Cancer

United States, Bulgaria, Italy, Korea, Republic of, Russian Federation, Spain, Turkey, Canada, Poland, Australia, Hungary, Taiwan, Japan, Germany, United Kingdom
German Breast Group
AstraZeneca

Completed

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (GeparOla)

Breast Cancer | Triple Negative Breast Neoplasms | HRpos Breast Neoplasms | BRCA 1 /2 and / or HRD

Germany
Medical University Innsbruck

Unknown

Characterization of Two Novel Mutations in the Apob Gene

Familial Hypobetalipoproteinaemia - Heterozygous Form | Low-LDL-syndrome

Austria
Scripps Health
J. Craig Venter Institute

Completed

Biomarker Monitoring in TP53 Mutation Carriers

Li-Fraumeni Syndrome | Hereditary Cancer Syndromes | TP53 Gene Germline Mutation Carrier

United States
Xueding Wang
Sun Yat-sen University

Unknown

A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment

Gastrointestinal Stromal Tumors | Somatic Mutation | Plasma Concentration | Germline Mutation

China

Search clinical trials for: germline heterozygous PTEN mutations

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations